{"id":31148,"date":"2025-02-17T08:52:18","date_gmt":"2025-02-17T07:52:18","guid":{"rendered":"https:\/\/ggba.swiss\/oculis-secures-usd-100-million-to-advance-its-neuroprotective-treatment-pipeline\/"},"modified":"2025-02-17T08:56:16","modified_gmt":"2025-02-17T07:56:16","slug":"oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/","title":{"rendered":"Oculis l\u00e8ve USD 100 millions pour ses traitements neuro-ophtalmiques"},"content":{"rendered":"\n<p><a href=\"https:\/\/oculis.com\/\">Oculis Holding AG<\/a>, une soci\u00e9t\u00e9 biopharmaceutique internationale sp\u00e9cialis\u00e9e dans les maladies ophtalmiques et neuro-ophtalmiques, a lev\u00e9 USD 100 millions dans le cadre d&rsquo;une offre sursouscrite de 5&rsquo;000&rsquo;000 d&rsquo;actions ordinaires \u00e0 USD 20.00 par action. Ce financement fait suite \u00e0 l&rsquo;offre directe de <a href=\"https:\/\/ggba.swiss\/fr\/oculis-realise-une-offre-directe-enregistree-sursouscrite-de-usd-59-millions\/\">USD 59 millions de la soci\u00e9t\u00e9 en avril 2024<\/a>, renfor\u00e7ant ainsi sa position sur le march\u00e9 apr\u00e8s sa double cotation au NASDAQ et au NASDAQ Islande.<\/p>\n\n\n\n<p>Le produit sera utilis\u00e9 pour faire progresser et acc\u00e9l\u00e9rer le portefeuille de d\u00e9veloppement clinique d&rsquo;Oculis, en particulier le d\u00e9veloppement de Privosegtor (OCS-05), un nouveau candidat neuroprotecteur pour la n\u00e9vrite optique aigu\u00eb avec des applications potentielles dans d&rsquo;autres maladies neuro-ophtalmiques. En outre, le financement servira \u00e0 soutenir le fonds de roulement et les besoins g\u00e9n\u00e9raux de l&rsquo;entreprise.<\/p>\n\n\n\n<p>L&rsquo;offre devrait \u00eatre cl\u00f4tur\u00e9e le 18 f\u00e9vrier 2025, sous r\u00e9serve des conditions de cl\u00f4ture habituelles. Avant la cl\u00f4ture, les nouvelles actions seront \u00e9mises \u00e0 partir de la tranche de capital existante de la soci\u00e9t\u00e9, portant le nombre total d&rsquo;actions enregistr\u00e9es \u00e0 53&rsquo;943&rsquo;700.<\/p>\n\n\n\n<p>BofA Securities et Leerink Partners ont agi en tant que teneurs de livre associ\u00e9s pour l&rsquo;offre, avec Pareto Securities en tant que chef de file et Arctica Finance en tant que conseiller financier. L&rsquo;offre a \u00e9t\u00e9 faite conform\u00e9ment \u00e0 une d\u00e9claration d&rsquo;enregistrement pr\u00e9alablement d\u00e9pos\u00e9e sur le formulaire F-3 aupr\u00e8s de la Securities and Exchange Commission (SEC) des \u00c9tats-Unis.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Traitements de nouvelle g\u00e9n\u00e9ration pour les troubles de la vision<\/h4>\n\n\n\n<p>Oculis s&rsquo;est impos\u00e9 comme un innovateur de premier plan dans le domaine des traitements ophtalmiques, avec un portefeuille de produits comprenant l&rsquo;OCS-01, un collyre topique pour l&rsquo;\u0153d\u00e8me maculaire diab\u00e9tique, le Privosegtor (OCS-05) pour la neuroprotection et le Licaminlimab (OCS-02), un candidat anti-TNF\u03b1 pour la s\u00e9cheresse oculaire. Bas\u00e9e en Suisse et pr\u00e9sente aux \u00c9tats-Unis et en Islande, Oculis continue d&rsquo;attirer d&rsquo;importants investissements internationaux dans le secteur de la sant\u00e9.<\/p>\n\n\n\n<p>Gr\u00e2ce \u00e0 ce dernier financement, Oculis est en mesure d&rsquo;acc\u00e9l\u00e9rer ses essais cliniques et ses progr\u00e8s r\u00e9glementaires, renfor\u00e7ant ainsi son r\u00f4le dans le d\u00e9veloppement de traitements de nouvelle g\u00e9n\u00e9ration pour les troubles de la vision.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oculis, une soci\u00e9t\u00e9 biopharmaceutique bas\u00e9e dans le canton de Vaud, a r\u00e9alis\u00e9 avec succ\u00e8s une offre publique de USD 100 millions, renfor\u00e7ant ainsi son portefeuille de traitements ophtalmiques et neuro-ophtalmiques innovants.<\/p>\n","protected":false},"author":6,"featured_media":31145,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1141],"class_list":["post-31148","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-personalized-medicine-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oculis l\u00e8ve USD 100M pour ses traitements neuro-ophtalmiques<\/title>\n<meta name=\"description\" content=\"Oculis a lev\u00e9 USD 100 millions pour renforcer son portefeuille de traitements ophtalmiques et neuro-ophtalmiques innovants.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oculis l\u00e8ve USD 100M pour ses traitements neuro-ophtalmiques\" \/>\n<meta property=\"og:description\" content=\"Oculis a lev\u00e9 USD 100 millions pour renforcer son portefeuille de traitements ophtalmiques et neuro-ophtalmiques innovants.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-17T07:52:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-17T07:56:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/02\/Oculis-Eye-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2360\" \/>\n\t<meta property=\"og:image:height\" content=\"1622\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Oculis l\u00e8ve USD 100 millions pour ses traitements neuro-ophtalmiques\",\"datePublished\":\"2025-02-17T07:52:18+00:00\",\"dateModified\":\"2025-02-17T07:56:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/\"},\"wordCount\":393,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/02\/Oculis-Eye-1180x811-1.jpeg\",\"keywords\":[\"Biotech\",\"Financing\",\"Personalized Medicine\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/\",\"name\":\"Oculis l\u00e8ve USD 100M pour ses traitements neuro-ophtalmiques\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/02\/Oculis-Eye-1180x811-1.jpeg\",\"datePublished\":\"2025-02-17T07:52:18+00:00\",\"dateModified\":\"2025-02-17T07:56:16+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Oculis a lev\u00e9 USD 100 millions pour renforcer son portefeuille de traitements ophtalmiques et neuro-ophtalmiques innovants.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/02\/Oculis-Eye-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/02\/Oculis-Eye-1180x811-1.jpeg\",\"width\":2360,\"height\":1622,\"caption\":\"Oculis d\u00e9veloppe des traitements ophtalmiques et neuroprotecteurs innovants pour r\u00e9pondre aux besoins m\u00e9dicaux non satisfaits dans le domaine des soins oculaires et des maladies neuro-ophtalmiques.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oculis l\u00e8ve USD 100 millions pour ses traitements neuro-ophtalmiques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oculis l\u00e8ve USD 100M pour ses traitements neuro-ophtalmiques","description":"Oculis a lev\u00e9 USD 100 millions pour renforcer son portefeuille de traitements ophtalmiques et neuro-ophtalmiques innovants.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/","og_locale":"fr_FR","og_type":"article","og_title":"Oculis l\u00e8ve USD 100M pour ses traitements neuro-ophtalmiques","og_description":"Oculis a lev\u00e9 USD 100 millions pour renforcer son portefeuille de traitements ophtalmiques et neuro-ophtalmiques innovants.","og_url":"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-02-17T07:52:18+00:00","article_modified_time":"2025-02-17T07:56:16+00:00","og_image":[{"width":2360,"height":1622,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/02\/Oculis-Eye-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Oculis l\u00e8ve USD 100 millions pour ses traitements neuro-ophtalmiques","datePublished":"2025-02-17T07:52:18+00:00","dateModified":"2025-02-17T07:56:16+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/"},"wordCount":393,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/02\/Oculis-Eye-1180x811-1.jpeg","keywords":["Biotech","Financing","Personalized Medicine"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/","url":"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/","name":"Oculis l\u00e8ve USD 100M pour ses traitements neuro-ophtalmiques","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/02\/Oculis-Eye-1180x811-1.jpeg","datePublished":"2025-02-17T07:52:18+00:00","dateModified":"2025-02-17T07:56:16+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Oculis a lev\u00e9 USD 100 millions pour renforcer son portefeuille de traitements ophtalmiques et neuro-ophtalmiques innovants.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/02\/Oculis-Eye-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/02\/Oculis-Eye-1180x811-1.jpeg","width":2360,"height":1622,"caption":"Oculis d\u00e9veloppe des traitements ophtalmiques et neuroprotecteurs innovants pour r\u00e9pondre aux besoins m\u00e9dicaux non satisfaits dans le domaine des soins oculaires et des maladies neuro-ophtalmiques."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/oculis-leve-usd-100-millions-pour-ses-traitements-neuro-ophtalmiques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Oculis l\u00e8ve USD 100 millions pour ses traitements neuro-ophtalmiques"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/31148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=31148"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/31148\/revisions"}],"predecessor-version":[{"id":31150,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/31148\/revisions\/31150"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/31145"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=31148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=31148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=31148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}